Xencor, Inc Deferred Tax Assets, Valuation Allowance
Xencor, Inc (XNCR) had Deferred Tax Assets, Valuation Allowance of $246.62 million as of 2025-12-31, per its 10-K filed 2026-02-25.
Financial Statements › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Components of Deferred Tax Assets › Deferred Tax Assets, Net › Deferred Tax Assets, Net of Valuation Allowance
us-gaap:DeferredTaxAssetsValuationAllowance · last filed 2026-02-25
- 2025-12-31: Deferred Tax Assets, Valuation Allowance $246.62M.
- 2024-12-31: Deferred Tax Assets, Valuation Allowance $227.27M; Deferred Tax Assets, Valuation Allowance as first filed $227.27M.
- 2023-12-31: Deferred Tax Assets, Valuation Allowance $170.45M; Deferred Tax Assets, Valuation Allowance as first filed $158.10M.
- 2022-12-31: Deferred Tax Assets, Valuation Allowance $116.21M; Deferred Tax Assets, Valuation Allowance as first filed $115.01M.
| Period end | Deferred Tax Assets, Valuation Allowance | Deferred Tax Assets, Valuation Allowance as first filed |
|---|---|---|
| 2025-12-31 | $246.62M 10-K · filed 2026-02-25 | |
| 2024-12-31 | $227.27M 10-K · filed 2026-02-25 | $227.27M 10-K · filed 2025-02-27 |
| 2023-12-31 | $170.45M 10-K · filed 2025-02-27 | $158.10M 10-K · filed 2024-02-29 |
| 2022-12-31 | $116.21M 10-K/A · filed 2025-02-24 | $115.01M 10-K · filed 2023-02-27 |
| 2021-12-31 | $93.58M 10-K · filed 2023-02-27 | |
| 2020-12-31 | $106.00M 10-K · filed 2022-02-24 | |
| 2019-12-31 | $77.39M 10-K · filed 2021-02-24 | |
| 2018-12-31 | $82.54M 10-K · filed 2020-02-25 | |
| 2017-12-31 | $57.66M 10-K · filed 2019-02-26 | $67.28M 10-K · filed 2018-02-28 |
| 2016-12-31 | $69.67M 10-K · filed 2018-02-28 | |
| 2015-12-31 | $76.04M 10-K · filed 2017-03-01 | |
| 2014-12-31 | $59.60M 10-K · filed 2016-03-08 | |
| 2013-12-31 | $84.05M 10-K · filed 2015-02-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Septerna, Inc. (SEPN) | United States | $1.783B | -63.01 |
| ANI PHARMACEUTICALS INC (ANIP) | United States | $1.810B | 18.77 |
| COMPASS Pathways plc (CMPS) | $1.812B | -4.87 | |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |